We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
IMAB

Price
3.98
Stock movement up
+0.02 (0.51%)
Company name
I-Mab
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
458.76M
Ent value
303.33M
Price/Sales
-
Price/Book
2.33
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-39.72%
1 year return
352.27%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2026-01-02

DIVIDENDS

IMAB does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.33
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count115.27M
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)-0.32

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash228.06M
Net receivables0.00
Total current assets232.78M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment3.17M
Total assets277.41M
Accounts payable0.00
Short/Current long term debt0.00
Total current liabilities16.09M
Total liabilities18.50M
Shareholder's equity258.92M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.96
Daily high4.06
Daily low3.90
Daily Volume431K
All-time high84.43
1y analyst estimate8.60
Beta1.46
EPS (TTM)-
Dividend per share0.00
Ex-div date-
Next earnings date1 Apr 2026

Downside potential

Loading...
Downside potential data
IMABS&P500
Current price drop from All-time high-95.29%-1.23%
Highest price drop-99.27%-19.00%
Date of highest drop7 Apr 20258 Apr 2025
Avg drop from high-97.29%-2.54%
Avg time to new high-6 days
Max time to new high308 days89 days
COMPANY DETAILS
IMAB (I-Mab) company logo
Marketcap
458.76M
Marketcap category
Small-cap
Description
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Employees
32
Investor relations
-
SEC filings
CEO
Huaqiong Shen
Country
USA
City
Pudong
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner